Chinook Therapeutics secures $86 mln in Series A financing
Chinook Therapeutics, a Vancouver-based developer of precision medicines for kidney disease, has raised about $86 million (US$65 million) in a Series A financing. U.S. life sciences venture capital firm Versant Ventures led the round, with participation from Apple Tree Partners and Samsara BioCapital. Chinook was incubated through Versant's Inception Sciences and seeded by Versant and Apple Tree. Chinook's technology leverages single-cell RNA sequencing, human-derived organoids and new translational models to develop therapeutics with novel mechanisms of action against kidney disease pathways. Led by President and CEO Eric Dobmeier, the company will use the funds raised to advance several programs into clinical trials by 2021.
22 August 2019•6 mins read
